Comparing 20/20 Biolabs (AIDX) and Its Rivals

20/20 Biolabs (NASDAQ:AIDX) is one of 238 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its competitors? We will compare 20/20 Biolabs to similar companies based on the strength of its profitability, analyst recommendations, risk, dividends, valuation, institutional ownership and earnings.

Institutional and Insider Ownership

58.0% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by company insiders. Comparatively, 15.2% of shares of all “Healthcare Providers & Services” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares 20/20 Biolabs and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
20/20 Biolabs Competitors	-6.55%	-155.80%	-1.44%

Earnings & Valuation

This table compares 20/20 Biolabs and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
20/20 Biolabs	$1.84 million	N/A	-1.52
20/20 Biolabs Competitors	$20.32 billion	$279.61 million	-241.31

20/20 Biolabs’ competitors have higher revenue and earnings than 20/20 Biolabs. 20/20 Biolabs is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for 20/20 Biolabs and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1	0	1	0	2.00
20/20 Biolabs Competitors	1754	7572	12974	770	2.55

20/20 Biolabs presently has a consensus target price of $5.00, indicating a potential upside of 1,076.19%. As a group, “Healthcare Providers & Services” companies have a potential upside of 13.62%. Given 20/20 Biolabs’ higher probable upside, equities research analysts plainly believe 20/20 Biolabs is more favorable than its competitors.

Summary

20/20 Biolabs beats its competitors on 6 of the 11 factors compared.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026. Both tests are run in our CAP (College of American Pathologists) accredited, CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory in Gaithersburg, MD. That laboratory also hosts our Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the U.S. without the expense of establishing and operating their own, independent lab. As noted above, during the COVID-19 pandemic, we also provided COVID-19 viral testing using polymerase chain reaction, or PCR, analytical equipment in our clinical laboratory. Our legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. As of the date of this prospectus, we generate revenue from three sources: OneTest for Cancer (primarily as a lab test in the U.S. but we also license our algorithms to overseas labs), BioCheck and from our CLIAx. For each of the nine months ended September 30, 2025 and 2024, sales of OneTest for Cancer accounted for approximately 87% of our revenues, sales of BioCheck accounted for approximately 9% of our revenues, and our CLIAx accounted for approximately 4% of our revenues. For the years ended December 31, 2024 and 2023, sales of OneTest for Cancer accounted for approximately 85% and 65% of our revenues, respectively, sales of BioCheck accounted for approximately 10% and 13% of our revenues, respectively, our CLIAx accounted for approximately 5% and 4% of our revenues, respectively, and COVID-19 testing accounted for approximately 0% and 18% of our revenues, respectively. Our principal executive offices are located in Gaithersburg, MD.